Company*
(Country;
Symbol)		 Product Description Indication Status (Date)
AUTOIMMUNE
BioMS
Medical Corp.
(Canada; TSE:MS)		 MBP8298 Synthetic peptide Multiple sclerosis Monitors in their fourth review of pivotal Phase II/III trial in secondary progressive MS recommended continuation of the study (5/3)
Chelsea
Therapeutics
International
Ltd. (CHTP)		 CH-1504 Orally available antifolate compound Rheumatoid arthritis Pilot study in 20 patients in Peru demonstrated safety, tolerability and efficacy (5/25)
ImmuPharma
plc (UK; LSE:IMM)		 IPP-201101 Agent that modulates the signaling of CD4+ cells Lupus Successfully completed Phase I trial in France and began Phase II proof-of-concept and efficacy study in Europe (5/10)
CANCER
Advaxis Inc.
(OTC BB:ADXS)		 Lovaxin C Listeria-based cancer vaccine Cervical cancer Began Phase I/II trials that will enroll 20 patients at sites in Israel, Serbia and Mexico (5/2)
Bioenvision
Inc. (BIVN)		 Evoltra (FDA-approved) Clofarabine; second- generation purine nucleoside analogue Pediatric acute lymphoblastic leukemia The product was approved in Europe for treating ALL in pediatric patients who have relapsed or are refractory to at least two prior regimens (5/31)
Chemokine
Therapeutics
Corp. (Canada;
OTC BB:CHKT)		 CTCE-9908 Chemokine CXCR4 antagonist Cancers Began Phase Ib/II trial in Canada to evaluate safety and preliminary efficacy in up to 30 patients with late-stage cancers (5/2)
Genentech
Inc. (NYSE:DNA)		 Herceptin (FDA-approved) Trastuzumab; monoclonal antibody against the HER2/neu protein Early stage breast cancer Partner F. Hoffmann-La Roche Ltd. gained approval in Europe in that additional indication (5/24)
Immutep SA*
(France)		 ImmuFact IMP321 T-cell immunostimulatory factor designed to amplify immune responses in therapeutic vaccines Cancers and viral diseases Phase I trials in 108 healthy volunteers in France demonstrated safety and tolerability, alone and with antigens (5/30)
OncoGenex
Technologies
Inc.* (Canada)
and Isis
Pharmaceuticals
Inc. (ISIS)		 OGX-011 Second-generation anti-sense drug designed to inhibit the production of clusterin, a cell-survival protein Non-small-cell lung cancer Eight of 9 patients in Phase I trial with gemcitabine and cisplatin showed either a partial response or stable disease; tolerability also was demonstrated (5/3)
Peplin Ltd.
(Australia;
ASX:PEP)		 PEP005 Topical Agent designed to kill cancer cells and stimulate an immune response Superficial basal cell carcinoma Phase IIa trial in Australia showed a statistically significant 71% reduction in sBCC tumors (5/1)
Prima BioMed
Ltd. (Australia;
ASX:PRR)		 CVac Autologous, mucin-1- based dendritic cell therapy Ovarian cancer Interim analysis from Phase IIa trial in advanced patients showed 21% of them had either a clinical response or disease stabilization (5/16)
Provectus
Pharmaceuticals
Inc. (OTC BB:PVCT)		 PV-10 (Provecta) Agent designed to be retained in tumor cells while leaving normal tissue unharmed Metastatic melanoma Phase I trial in 20 subjects in Australia demonstrated safety and evidence of efficacy (5/15)
PTC
Therapeutics
Inc.*		 PTC299 Small-molecule compound designed to inhibit vascular endothelial growth factor in tumors Cancer Began Phase Ia trial in Belgium to evaluate safety and pharmaco-kinetics in healthy volunteers (5/12)
CENTRAL NERVOUS SYSTEM
Antipodean
Pharmaceuticals
Inc.*		 MitoQ Mitoquinone; antioxidants delivered by targeted lipophilic cations Parkinson's disease Began Phase II trial in Australia and New Zealand that will evaluate efficacy (5/25)
Celtic
Pharmaceutical
Holdings LP*
(Bermuda)		 TA-NIC Vaccine designed to raise anti-nicotine antibodies Nicotine addiction Is starting a Phase II trial that will enroll more than 400 patients in Europe (5/8)
INFECTION
BioInvent
International
AB (Sweden;
SSE:BINV)		 BI-201 Human antibody that binds to the TAT protein HIV Phase I/IIa trial showed tolerability but no reduction of HIV levels; it plans to test more patients at higher doses (5/29)
Crucell NV
(the Netherlands;
CRXL)		 -- Three different vaccine formulations, all based on the H9N2 virus Avian influenza Began study in the UK to assess safety and immunogenicity of the vaccines in 560 healthy adults (5/31)
Intercell AG
(Austria;
VSE:ICLL)		 -- Inactivated vaccine against Japanese encephalitis virus Japanese encephalitis virus Pivotal Phase III trial in 868 subjects met primary endpoint of demonstrating immunogenicity (5/31)
MISCELLANEOUS
Tercica Inc.
(TRCA)		 Increlex (FDA-approved) Mecasermin injection; recombinant human insulin-like growth factor-1 Primary IGF-1 deficiency The product was granted orphan status in Europe in that indication (5/31)
Manhattan
Pharmaceuticals
Inc. (AMEX:MHA)		 OE Oral administered, synthetic form of form of Oleoyl-estrone Obesity Is starting Phase IIa trial in 100 subjects in Switzerland to assess safety, preliminary efficacy and pharmacokinetics (5/16)
Notes:
* Privately held.
MAA = Marketing authorization application; MRP = Mutual Recognition Procedure; EMEA = European Medicines Agency.
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vienna Stock Exchange.